Clinical Trials Logo

Postmenopausal Osteoporosis clinical trials

View clinical trials related to Postmenopausal Osteoporosis.

Filter by:

NCT ID: NCT02791516 Completed - Clinical trials for Postmenopausal Osteoporosis

A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

Start date: January 16, 2017
Phase: Phase 3
Study type: Interventional

The primary objective is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy X-ray absorptiometry (DXA) in postmenopausal women with osteoporosis.

NCT ID: NCT02604836 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia

Start date: June 2004
Phase: Phase 4
Study type: Interventional

This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate. The anticipated time on study treatment is 6 months, and the target sample size is 1776 individuals.

NCT ID: NCT02598453 Completed - Clinical trials for Postmenopausal Osteoporosis

PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia

Start date: January 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate treatment adherence to different regimens of ibandronate in postmenopausal women with osteoporosis or osteopenia who are intolerant to daily or weekly alendronate or risedronate therapy due to gastrointestinal (GI) side effects. The anticipated time on study treatment is 12 months, and the target sample size is 517 individuals.

NCT ID: NCT02598440 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis

Start date: March 2004
Phase: Phase 4
Study type: Interventional

This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis. The anticipated time of study treatment is 6 months, and the target sample size is 338 individuals.

NCT ID: NCT02499237 Completed - Clinical trials for Postmenopausal Osteoporosis

Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation

AfterDmab
Start date: July 2015
Phase: Phase 4
Study type: Interventional

In contrast with bisphosphonates,discontinuation of denosumab results in gradual loss of bone mineral density gains. The investigators aim to evaluate whether in patients treated with denosumab, a single zoledronic acid infusion would prevent the anticipated bone loss.

NCT ID: NCT02478879 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

Start date: June 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine which of two delivery methods of Parathyroid Hormone (PTH) is preferred by patients after 14 days of use for each.

NCT ID: NCT02422069 Completed - Clinical trials for Postmenopausal Osteoporosis

Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in Pakistan

Start date: April 2010
Phase: N/A
Study type: Observational

This observational study will provide an opportunity to document local patterns of susceptibility, patient profile, and usefulness of screening in postmenopausal patients coming to gynecology outpatient clinics in Pakistan. This will also capture the initial management of PMO in diagnosed patients. The information gathered will serve as a foundation for developing national guidelines on screening and management of PMO in Pakistan.

NCT ID: NCT02234414 Completed - Clinical trials for Postmenopausal Osteoporosis

Epidemiology, Identification Rate and Treatment Penetration of Osteoporotic Vertebral Fractures in Switzerland

SwOF
Start date: February 2009
Phase: N/A
Study type: Observational

In Switzerland, the prevalence of vertebral fractures in community- dwelling women is unknown and the published data from the Swiss hospitals statistics represent only the tip of the iceberg. In addition, the percentages of women correctly identified with vertebral fractures due to osteoporosis and the treatment rate of these women with a drug proven to reduce the risk of further fractures are unknown. Furthermore, it is not known whether the prevalence of vertebral fractures differs between urban and rural areas or between mountain areas and plain country, e.g. due to possible differences in sun exposure (vitamin D production) and/ or in physical activity and/ or dietary habits. Clinical signs and symptoms leading to the suspicion of vertebral fracture(s) lack either sensitivity (wall-occiput distance) or specificity (rib-pelvis distance). Whether a combination of both would improve sensitivity and specificity is unknown. The gold standard for the diagnosis of vertebral fracture relies on antero-posterior and lateral X-Rays of the thoracic and lumbar spine. Despite standardization of X-Ray readings, a retrospective study of hospitalized elderly patients has shown that as many as 50% of the radiographic reports failed to note the presence of moderate to severe vertebral fractures. In a primary care setting, fewer than 2% of the women received diagnoses of osteoporosis or vertebral fracture, although expected prevalence is 20% to 30% and appropriate drug treatment was offered to only 36% of the diagnosed patients. The recent availability of software for vertebral fracture assessment (VFA) coupled to DXA measurements allows for the detection of vertebral deformities, which is critical for management of osteoporosis, as the existence of such deformities substantially increases the risk of subsequent fracture. Recently published results show that VFA allows the diagnosis of a vertebral fracture. The sensitivity of VFA for detection of vertebral fractures compared to expert radiologist reading of X-ray is excellent for grade 2 and 3 fractures, ranging between 90-94%.

NCT ID: NCT02176382 Completed - Clinical trials for Postmenopausal Osteoporosis

Denosumab and Teriparatide Study (DATA-HD and DATA-EX)

DATA-HD
Start date: August 2014
Phase: Phase 4
Study type: Interventional

The aim of the study is to assess the effect of an antiresorptive medication in combination with standard dose or alternate dose teriparatide. The study extension will evaluate the effect of one-dose of zoledronic acid after the teriparatide/denosumab combination.

NCT ID: NCT02157948 Completed - Clinical trials for Postmenopausal Osteoporosis

A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

Start date: May 2014
Phase: Phase 3
Study type: Interventional

This study will compare the effect of denosumab produced by two different manufacturing processes on bone mineral density at the lumbar spine in postmenopausal women with osteoporosis.